person

Paolo L.

Country
Italy
Department
Oftalmologia

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
108
Sites with multiple studies

Has run more than one trial at 108 of 162 partner sites.

Specializations

Neovascular AMD Research

This investigator specializes in treating neovascular age-related macular degeneration (nAMD), with particular focus on innovative delivery systems and combination therapies. Their research encompasses the evaluation of port delivery systems and novel therapeutic approaches for managing wet AMD.

  • Long-term treatment outcomes
  • Sustained drug delivery mechanisms
  • Gene therapy applications

The investigator explores various treatment intervals and delivery methods to optimize patient care in nAMD management.

Retinal Disease Management

Their expertise extends to various forms of macular disorders, including diabetic macular edema and geographic atrophy. The investigator evaluates novel therapeutic compounds and their applications in treating different types of retinal conditions.

  • Visual acuity assessment
  • Intravitreal therapeutics
  • Anti-VEGF treatments

Research activities focus on comparing treatment efficacy across different therapeutic approaches for retinal diseases.

Advanced Therapeutic Development

The investigator works with emerging therapeutic modalities including subcutaneous treatments and combination therapies for various forms of AMD. Their research encompasses both dry and wet AMD treatment approaches.

  • Novel drug formulations
  • Treatment optimization strategies
  • Long-term safety assessments

Their work includes evaluation of innovative therapeutic compounds and delivery methods for macular degeneration.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.